2026-03-31
Poultry producers are facing increased challenges from infectious diseases that impact productivity and flock health. Newcastle Disease (ND) and Avian Influenza (AI), particularly Low Pathogenic Avian Influenza (LPAI) H9N2, are significant concerns, especially in regions like the Middle East, Asia, and Africa due to continuous virus circulation, high stocking density, and environmental stress. LPAI H9N2 often causes mild or subclinical signs but has immunosuppressive effects that increase susceptibility to secondary infections, such as ND. Field observations indicate simultaneous occurrences of ND and AI. Separate vaccinations create labor demands, chicken stress, and operational complexity, emphasizing the need for efficient vaccination strategies.
To address these issues, Medivac ND G7-AI H9N2 has been developed as a practical dual-protection solution. This inactivated vaccine combines Newcastle Disease virus genotype VII with LPAI H9N2. It delivers protection against two major respiratory threats in a single injection, supporting stronger immune responses and reducing vaccination workload.
A controlled Specific Pathogen Free (SPF) chickens trial confirmed that Medivac ND G7-AI H9N2 induces strong, reliable immunity against both ND Genotype VII and LPAI H9N2. Birds vaccinated at 28 days achieved HI titers well above standard benchmarks within three weeks: HI 29.3 for ND GVII and HI 210.7 for H9N2, demonstrating robust, genotype-matched dual protection from a single shot.
Flexible Administration Across Poultry Sectors
Medivac ND G7-AI H9N2 offers flexible administration options:
Broilers: A 0.2 mL subcutaneous dose during the first week provides early protection and simplifies the vaccination schedule.
Layers & Breeders: The vaccine ensures stability from the pullet phase into production. Trials in pullets vaccinated at 4 days and 8 weeks resulted in antibody titers above standard levels, ensuring optimal immunity prior to laying.
Laying Period Chickens: Trials in chickens vaccinated at 15 and 36 weeks demonstrated protective antibody titers throughout the production period, ensuring sustained immunity against ND Genotype VII and LPAI H9N2 from rearing to the end of the laying cycle.
Supporting Sustainable Poultry Production
While vaccination is crucial, optimal disease control also requires strict biosecurity measures and sound farm management practices. Backed by Medion’s commitment to innovation and quality, Medivac ND G7-AI H9N2 supports sustainable poultry production under challenging field conditions.
